Evidence map›Paper›PMID 42450065›Full record

ArticleInternational journal of molecular sciences2026

Profiles of FGF2, HGF, Fas/CD95, CASP9, ALDH1A1, and GLUT1 in GEP-NETs: A Comparative Tumor-Margin Study Based on Protein Concentration.

Agata Świętek, Joanna Katarzyna Strzelczyk, Dorota Hudy, Zenon P Czuba, Karolina Snopek-Miśta, Mariusz Kryj, Katarzyna Kuśnierz, Marcin Zeman, Władysław Skałba, Agata Abramowicz and 1 more

Abstract readComparative Study
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Agata ŚwiętekDepartment of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-808 Zabrze, Poland.ORCID 0000-0002-3465-0664
Joanna Katarzyna StrzelczykDepartment of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-808 Zabrze, Poland.ORCID 0000-0002-3686-5685
Dorota HudyDepartment of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-808 Zabrze, Poland.ORCID 0000-0002-9110-2314
Zenon P CzubaDepartment of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-808 Zabrze, Poland.ORCID 0000-0001-8216-4495
Karolina Snopek-MiśtaDepartment of Oncological Surgery, Prof. Kornel Gibiński Independent Public Central Clinical Hospital, Medical University of Silesia in Katowice, 35 Ceglana St., 40-514 Katowice, Poland.
Mariusz KryjDepartment of Oncological Surgery, Prof. Kornel Gibiński Independent Public Central Clinical Hospital, Medical University of Silesia in Katowice, 35 Ceglana St., 40-514 Katowice, Poland.
Katarzyna KuśnierzDepartment of Gastrointestinal Surgery, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, 14 Medyków St., 40-752 Katowice, Poland.ORCID 0000-0001-8374-028X
Marcin ZemanIII Department of Oncological Surgery, Gliwice Branch, Maria Sklodowska-Curie National Research Institute of Oncology, 15 Wybrzeże Armii Krajowej Str., 44-100 Gliwice, Poland.
Władysław SkałbaIII Department of Oncological Surgery, Gliwice Branch, Maria Sklodowska-Curie National Research Institute of Oncology, 15 Wybrzeże Armii Krajowej Str., 44-100 Gliwice, Poland.
Agata AbramowiczDepartment of Clinical and Molecular Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, ul. Wybrzeże Armii Krajowej, 44-102 Gliwice, Poland.ORCID 0000-0002-7826-9398
Janusz StrzelczykDepartment of Endocrinology and Neuroendocrine Tumors, Department of Pathophysiology and Endocrinology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 35 Ceglana St., 40-514 Katowice, Poland.ORCID 0000-0002-7987-7344

Funding

Medical University of Silesia BNW-1-004/N/4/O
6 · The paper itself

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are characterized by substantial biological heterogeneity and complex regulation of apoptosis, metabolism, and angiogenesis. The aim of this study was to evaluate the concentrations of selected proteins: FGF2, HGF, Fas/CD95, CASP9, ALDH1A1, and GLUT1 in tumor and margin samples and assess correlations with clinical and demographic parameters. A total of 59 samples from patients with GEP-NETs were analyzed using multiplex immunoassay and ELISA methods. Significant differences in protein expression between tumor and margin tissues were observed. Fas/CD95 levels were lower in tumor samples, whereas HGF concentration was higher. Elevated HGF, FGF2 and Fas/CD95 levels were associated with advanced tumor stage. HGF and GLUT1 concentrations varied depending on nodal status, while FGF2, Fas/CD95, and CASP9 levels were increased in metastatic cases. Additionally, differences related to tumor localization and the influence of smoking and alcohol consumption were identified. Dysregulation of apoptotic, metabolic, and angiogenic pathways plays a crucial role in GEP-NETs progression and highlights the importance of the tumor microenvironment. GEP-NET exhibit biological heterogeneity and complex progression driven by multiple interacting molecular pathways. The factors analyzed may have potential significance as biomarkers of disease progression; however, their exact role requires further investigation in larger, prospective cohorts.

Indexed as

fas ReceptorFibroblast Growth Factor 2Glucose Transporter Type 1Hepatocyte Growth FactorNeuroendocrine TumorsPancreatic NeoplasmsAgedAldehyde Dehydrogenase 1 FamilyBiomarkers, TumorCaspase 9FemaleHumansMaleMiddle AgedRetinal DehydrogenaseAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanBiomarkers, TumorCASP9 protein, humanCaspase 9FAS protein, humanfas ReceptorFibroblast Growth Factor 2Glucose Transporter Type 1Hepatocyte Growth FactorHGF protein, humanRetinal DehydrogenaseSLC2A1 protein, humanaldehyde dehydrogenase 1A1 (ALDH1A1)caspase-9 (CASP9)cluster of differentiation 95 (Fas/CD95)fibroblast growth factor 2 (FGF2)gastroenteropancreatic neuroendocrine tumors (GEP-NETs)glucose transporter 1 (GLUT1)hepatocyte growth factor (HGF)marginprotein concentrationtumor

Identifiers

PMID42450065
PMCPMC13362495

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.